Arcutis Biotherapeutics Inc [ARQT] stock prices are up 3.34% to $20.72 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ARQT shares have gain 4.86% over the last week, with a monthly amount glided 19.84%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcutis Biotherapeutics Inc [NASDAQ: ARQT] stock has seen the most recent analyst activity on July 25, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $18. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 30, 2024, and set its price target to $19. On August 28, 2024, Jefferies initiated with a Buy rating and assigned a price target of $15 on the stock. Mizuho upgraded its rating to a Buy and increased its price target to $8 on January 03, 2024. Mizuho downgraded its rating to a Neutral and reduced its price target to $4 on October 26, 2023. Goldman downgraded its rating to Neutral for this stock on October 13, 2023, and downed its price target to $6. In a note dated September 07, 2022, Needham initiated an Buy rating and provided a target price of $46 on this stock.
The stock price of Arcutis Biotherapeutics Inc [ARQT] has been fluctuating between $8.03 and $21.56 over the past year. Currently, Wall Street analysts expect the stock to reach $27 within the next 12 months. Arcutis Biotherapeutics Inc [NASDAQ: ARQT] shares were valued at $20.72 at the most recent close of the market. An investor can expect a potential return of 30.31% based on the average ARQT price forecast.
Analyzing the ARQT fundamentals
The Arcutis Biotherapeutics Inc [NASDAQ:ARQT] reported sales of 263.46M for trailing twelve months, representing a surge of 164.13%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -0.33%, Pretax Profit Margin comes in at -0.35%, and Net Profit Margin reading is -0.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.63 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.79.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Arcutis Biotherapeutics Inc [NASDAQ:ARQT]’s Current Ratio is 3.20. On the other hand, the Quick Ratio is 3.04, and the Cash Ratio is 0.7. Considering the valuation of this stock, the price to sales ratio is 9.43, the price to book ratio is 17.86.
Transactions by insiders
Recent insider trading involved Edwards Larry Todd, that happened on Oct 02 ’25 when 4504.0 shares were sold. Watanabe Todd completed a deal on Oct 01 ’25 to sell 24261.0 shares. Meanwhile, Watanabe Todd sold 20739.0 shares on Oct 02 ’25.
